Lantern Pharma (NASDAQ:LTRN) Announces Earnings Results, Misses Estimates By $0.03 EPS

Lantern Pharma (NASDAQ:LTRN) issued its quarterly earnings data on Thursday. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.03), Zacks reports.

Lantern Pharma Stock Performance

Shares of LTRN traded down $0.09 on Friday, reaching $3.63. The stock had a trading volume of 32,761 shares, compared to its average volume of 83,882. Lantern Pharma has a 12-month low of $2.79 and a 12-month high of $10.06. The firm has a market capitalization of $39.15 million, a price-to-earnings ratio of -2.04 and a beta of 1.64. The company has a 50-day simple moving average of $4.26 and a 200-day simple moving average of $3.78.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.